JP2017524712A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524712A5 JP2017524712A5 JP2017507390A JP2017507390A JP2017524712A5 JP 2017524712 A5 JP2017524712 A5 JP 2017524712A5 JP 2017507390 A JP2017507390 A JP 2017507390A JP 2017507390 A JP2017507390 A JP 2017507390A JP 2017524712 A5 JP2017524712 A5 JP 2017524712A5
- Authority
- JP
- Japan
- Prior art keywords
- injection
- composition
- particle
- glucocorticoid
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002245 particle Substances 0.000 claims description 37
- 239000007924 injection Substances 0.000 claims description 29
- 238000002347 injection Methods 0.000 claims description 29
- 239000003862 glucocorticoid Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 12
- 239000002105 nanoparticle Substances 0.000 claims description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 claims description 6
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 claims description 6
- 206010029113 Neovascularisation Diseases 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 229920002988 biodegradable polymer Polymers 0.000 claims description 4
- 239000004621 biodegradable polymer Substances 0.000 claims description 4
- 230000009920 chelation Effects 0.000 claims description 4
- 229910021645 metal ion Inorganic materials 0.000 claims description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 4
- 230000000717 retained effect Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000013268 sustained release Methods 0.000 claims description 3
- 239000012730 sustained-release form Substances 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 229920001273 Polyhydroxy acid Polymers 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 210000002159 anterior chamber Anatomy 0.000 claims description 2
- 229920001400 block copolymer Polymers 0.000 claims description 2
- 230000009918 complex formation Effects 0.000 claims description 2
- 229920006237 degradable polymer Polymers 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000903 polyhydroxyalkanoate Polymers 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 description 11
- 206010046851 Uveitis Diseases 0.000 description 4
- 208000002691 Choroiditis Diseases 0.000 description 2
- 206010055665 Corneal neovascularisation Diseases 0.000 description 2
- 208000003971 Posterior uveitis Diseases 0.000 description 2
- 201000000159 corneal neovascularization Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010022557 Intermediate uveitis Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000007407 panuveitis Diseases 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462037000P | 2014-08-13 | 2014-08-13 | |
| US62/037,000 | 2014-08-13 | ||
| US201562139561P | 2015-03-27 | 2015-03-27 | |
| US62/139,561 | 2015-03-27 | ||
| PCT/US2015/043478 WO2016025215A1 (en) | 2014-08-13 | 2015-08-03 | Glucocorticoid-loaded nanoparticles for prevention of corneal allograft rejection and neovascularization |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017524712A JP2017524712A (ja) | 2017-08-31 |
| JP2017524712A5 true JP2017524712A5 (enExample) | 2018-08-16 |
Family
ID=54011072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017507390A Pending JP2017524712A (ja) | 2014-08-13 | 2015-08-03 | 角膜同種移植片拒絶および新血管形成を予防するためのグルココルチコイドを負荷したナノ粒子 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10195212B2 (enExample) |
| EP (1) | EP3193827A1 (enExample) |
| JP (1) | JP2017524712A (enExample) |
| KR (1) | KR20170046146A (enExample) |
| CN (1) | CN106794152A (enExample) |
| CA (1) | CA2957764C (enExample) |
| MX (1) | MX2017001863A (enExample) |
| WO (1) | WO2016025215A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889193B2 (en) | 2010-02-25 | 2014-11-18 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| EP3233098B1 (en) | 2014-12-15 | 2024-05-29 | The Johns Hopkins University | Cvs transplantation for treatment of bacterial vaginosis |
| CN107278151A (zh) | 2014-12-15 | 2017-10-20 | 约翰霍普金斯大学 | 舒尼替尼制剂及其在治疗青光眼中的使用方法 |
| CN107635545A (zh) | 2015-01-27 | 2018-01-26 | 约翰霍普金斯大学 | 用于增强粘膜表面处活性剂的输送的低渗水凝胶制剂 |
| KR20180058758A (ko) | 2015-09-22 | 2018-06-01 | 그레이버그 비젼, 인크. | 안구 장애의 치료를 위한 화합물 및 조성물 |
| BR112018009644A2 (pt) | 2015-11-12 | 2018-11-06 | Graybug Vision Inc | micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície |
| DE102017002454A1 (de) * | 2017-03-14 | 2018-09-20 | Friedrich-Schiller-Universität Jena | Organische Polymerpartikel enthaltend Poly(oxazolin)-Stabilisatoren und Verwendung von Poly(oxazolinen) zur Stabilisierung von organischen Polymerpartikeln |
| JP7217022B2 (ja) | 2017-03-23 | 2023-02-02 | グレイバグ ビジョン インコーポレイテッド | 眼障害の治療のための薬物及び組成物 |
| CA3057875A1 (en) | 2017-05-10 | 2018-11-15 | Graybug Vision, Inc. | Extended release microparticles and suspensions thereof for medical therapy |
| WO2019071275A1 (en) * | 2017-10-06 | 2019-04-11 | Aciont Inc. | DEVICES FOR DELIVERY OF NON-INVASIVE OCULAR MEDICINE |
| WO2020210805A1 (en) * | 2019-04-11 | 2020-10-15 | The Johns Hopkins University | Nanoparticles for drug delivery to brain |
| WO2021168239A1 (en) * | 2020-02-21 | 2021-08-26 | The Johns Hopkins University | Suprachoroidal delivery of drug particles to reduce toxicity |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4432964A (en) * | 1981-08-24 | 1984-02-21 | Alza Corporation | Topical composition containing steroid in two forms released independently from polymeric carrier |
| US4888176A (en) | 1984-05-21 | 1989-12-19 | Massachusetts Institute Of Technology | Controlled drug delivery high molecular weight polyanhydrides |
| US4757128A (en) | 1986-08-01 | 1988-07-12 | Massachusetts Institute Of Technology | High molecular weight polyanhydride and preparation thereof |
| US4789724A (en) | 1986-10-17 | 1988-12-06 | Massachusetts Institute Of Technology | Preparation of anhydride copolymers |
| US4857311A (en) | 1987-07-31 | 1989-08-15 | Massachusetts Institute Of Technology | Polyanhydrides with improved hydrolytic degradation properties |
| US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| WO2004084871A1 (en) * | 2003-03-26 | 2004-10-07 | Ltt Bio-Pharma Co., Ltd. | Intravenous nanoparticles for targenting drug delivery and sustained drug release |
| US20090148527A1 (en) * | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
| US20050226814A1 (en) | 2004-04-13 | 2005-10-13 | Bausch & Lomb Incorporated | Diagnostic method and kit for implantation of a sustained release drug-delivery implant with a steroid |
| US20060089590A1 (en) * | 2004-10-27 | 2006-04-27 | John Higuchi | Methods and devices for sustained in-vivo release of an active agent |
| JP2007001926A (ja) * | 2005-06-24 | 2007-01-11 | Ltt Bio-Pharma Co Ltd | 吸入・噴霧用ステロイド製剤 |
| EP1985309B1 (en) * | 2005-12-26 | 2016-11-23 | LTT Bio-Pharma Co., Ltd. | Nanoparticles containing water-soluble non-peptide low-molecular weight drug |
| US20100129456A1 (en) * | 2007-05-14 | 2010-05-27 | Ltt Bio-Pharma Co., Ltd. | Sustained-release nanoparticle containing low-molecular-weight drug with negatively charged group |
| JP2011512903A (ja) * | 2008-02-25 | 2011-04-28 | アイゲート ファーマ エスエーエス | イオントフォレシスを介した眼組織への治療薬の向上した送達 |
| US20110206773A1 (en) * | 2008-05-20 | 2011-08-25 | Yale University | Sustained delivery of drugs from biodegradable polymeric microparticles |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| WO2011041373A1 (en) | 2009-09-29 | 2011-04-07 | Eyegate Pharmaceuticals, Inc. | Positively-charged poly (d,l-lactide-co-glycolide) nanoparticles and fabrication methods of the same |
| CA2845673A1 (en) | 2011-09-13 | 2013-03-21 | Altacor Limited | Pharmaceutical nanoparticle compositions |
| AU2013209452B2 (en) | 2012-01-19 | 2015-11-05 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
| NZ741873A (en) * | 2012-05-03 | 2019-04-26 | Kala Pharmaceuticals Inc | Pharmaceutical nanoparticles showing improved mucosal transport |
-
2015
- 2015-08-03 JP JP2017507390A patent/JP2017524712A/ja active Pending
- 2015-08-03 EP EP15756267.9A patent/EP3193827A1/en not_active Withdrawn
- 2015-08-03 KR KR1020177006811A patent/KR20170046146A/ko not_active Withdrawn
- 2015-08-03 WO PCT/US2015/043478 patent/WO2016025215A1/en not_active Ceased
- 2015-08-03 MX MX2017001863A patent/MX2017001863A/es unknown
- 2015-08-03 CN CN201580053822.9A patent/CN106794152A/zh active Pending
- 2015-08-03 US US15/502,732 patent/US10195212B2/en active Active
- 2015-08-03 CA CA2957764A patent/CA2957764C/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524712A5 (enExample) | ||
| Pan et al. | Corticosteroid-loaded biodegradable nanoparticles for prevention of corneal allograft rejection in rats | |
| CN104136006B (zh) | 悬浮在凝固性储库形成可注射药物制剂中的随时间推移而释放的生物可降解或生物可蚀解微球粒或微粒 | |
| Salama et al. | PLGA nanoparticles as subconjunctival injection for management of glaucoma | |
| Nanjawade et al. | RETRACTED: In situ-forming hydrogels for sustained ophthalmic drug delivery | |
| JP6132964B2 (ja) | 萎縮性加齢性黄斑変性の処置方法 | |
| JP2022001582A (ja) | 眼において薬物徐放を達成する方法及び生体適合性組成物 | |
| JP5274315B2 (ja) | 結膜下デポによるドラッグデリバリーシステム | |
| JP2018171519A (ja) | 持続型薬物送達インプラント | |
| CN107613985B (zh) | 含有糖皮质激素的纳米微粒的水性悬浮液剂 | |
| CA2957764C (en) | Glucocorticoid-loaded nanoparticles for prevention of corneal allograft rejection and neovascularization | |
| WO2003070219A1 (en) | Drug delivery system for the subconjunctival administration of fine grains | |
| JP2015007117A (ja) | 眼内徐放型ドラッグ送達システムおよび眼症状を処置する方法 | |
| JP2020519585A5 (enExample) | ||
| Panda et al. | RETRACTED: Self-assembled phenylalanine-α, β-dehydrophenylalanine nanotubes for sustained intravitreal delivery of a multi-targeted tyrosine kinase inhibitor | |
| Peter et al. | A review on newer ocular drug delivery systems with an emphasis on glaucoma | |
| WO2005018608A1 (ja) | 微粒子テノン嚢下投与ドラッグデリバリーシステム | |
| Bayram et al. | Preparation and characterization of triamcinolone acetonide-loaded poly (3-hydroxybutyrate-co-3-hydroxyhexanoate)(PHBHx) microspheres | |
| JP4487141B2 (ja) | 微粒子テノン嚢下投与ドラッグデリバリーシステム | |
| 민창희 | IONTOPHORETIC DELIVERY OF DRUG-LOADED PLGA NANOPARTICLES TO THE PREOCULAR SURFACE FOR ENHANCED DRUG BIOAVAILABILITY | |
| Pawar et al. | Progress, prospect and explorations of polymeric nanoparticles for the treatment of ophthalmic complications. | |
| Lavik et al. | Sustained intraocular delivery of drugs from biodegradable polymeric microparticles | |
| Tawfik | Dual Drug-Loaded Electrospun Nanofibres for the Treatment of Corneal Diseases | |
| JP2006257080A (ja) | ステロイド化合物の副作用軽減または回避方法 | |
| RU2021117158A (ru) | Улучшенные агрегированные микрочастицы |